DNLI
Denali Therapeutics Inc.
$19.62
-0.46%
2026-05-08
About Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Key Fundamentals
Forward P/E
-7.57
EPS (TTM)
$-2.97
ROE
-45.7%
Profit Margin
0.0%
Debt/Equity
4.17
Price/Book
3.01
Beta
0.99
Market Cap
$3.10B
Avg Volume (10D)
1.9M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$23.46
60D Low
$17.86
Avg Volume
1.7M
Latest Close
$19.62
Get breakout alerts for DNLI
Sign up for Breakout Scanner to receive daily notifications when DNLI triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Denali Therapeutics Inc. (DNLI) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors DNLI daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. DNLI operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.